APA
LoRusso P. M., Boerner S. A., Pilat M. J., Forman K. M., Zuccaro C. Y., Kiefer J. A., Liang W. S., Hunsberger S., Redman B. G., Markovic S. N., Sekulic A., Bryce A. H., Joseph R. W., Cowey C. L., Fecher L. A., Sosman J. A., Chapman P. B., Schwartz G. K., Craig D. W., Carpten J. D. & Trent J. M. (20160505). Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. : Molecular cancer therapeutics.
Chicago
LoRusso Patricia M, Boerner Scott A, Pilat Mary Jo, Forman Karen M, Zuccaro Clarice Y, Kiefer Jeffrey A, Liang Winnie S, Hunsberger Sally, Redman Bruce G, Markovic Svetomir N, Sekulic Aleksandar, Bryce Alan H, Joseph Richard W, Cowey C Lance, Fecher Leslie Anne, Sosman Jeffrey Alan, Chapman Paul B, Schwartz Gary K, Craig David W, Carpten John D and Trent Jeffrey M. 20160505. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. : Molecular cancer therapeutics.
Harvard
LoRusso P. M., Boerner S. A., Pilat M. J., Forman K. M., Zuccaro C. Y., Kiefer J. A., Liang W. S., Hunsberger S., Redman B. G., Markovic S. N., Sekulic A., Bryce A. H., Joseph R. W., Cowey C. L., Fecher L. A., Sosman J. A., Chapman P. B., Schwartz G. K., Craig D. W., Carpten J. D. and Trent J. M. (20160505). Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. : Molecular cancer therapeutics.
MLA
LoRusso Patricia M, Boerner Scott A, Pilat Mary Jo, Forman Karen M, Zuccaro Clarice Y, Kiefer Jeffrey A, Liang Winnie S, Hunsberger Sally, Redman Bruce G, Markovic Svetomir N, Sekulic Aleksandar, Bryce Alan H, Joseph Richard W, Cowey C Lance, Fecher Leslie Anne, Sosman Jeffrey Alan, Chapman Paul B, Schwartz Gary K, Craig David W, Carpten John D and Trent Jeffrey M. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. : Molecular cancer therapeutics. 20160505.